Observational studyMedicine2025
Impact of medical history of severe COVID-19 infection on serum cytokine levels and prognosis in patients with sepsis: A prospective observational study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A history of severe COVID-19 may have lasting effects on immune and coagulation dysfunction, potentially influencing sepsis outcomes. This study investigates the impact of severe COVID-19 history on inflammatory markers, coagulation parameters, and prognosis in sepsis patients. This prospective observational study included 181 sepsis patients, comprising 28 with a history of severe COVID-19 infection and 153 without such a history, admitted between October 2021 and May 2023. Serum C-reactive protein (CRP), Interleukin (IL)-6, IL-1β, IL-17, and Tumor necrosis factor-α were measured by enzyme-linked immunosorbent assay (ELISA). Coagulation markers activated partial thromboplastin time (APTT), prothrombin time (PT) and D-dimer (D-D), inflammatory factor procalcitonin (PCT), and severity scores sequential organ failure assessment and acute physiology and chronic health evaluation II were assessed. Kaplan-Meier survival analysis and multivariate logistic regression were used to evaluate 28-day mortality and associated risk factors. Patients with severe COVID-19 history showed significantly higher sequential organ failure assessment and acute physiology and chronic health evaluation II scores, along with elevated APTT, PCT, IL-6, IL-1β, and IL-17 levels. CRP and tumor necrosis factor-α levels did not differ significantly. Among patients with poor prognosis, IL-6, IL-17, and APTT levels were higher, and a larger proportion had a history of severe COVID-19 (36.8% vs 5.6%). Kaplan-Meier analysis showed reduced 28-day survival in the severe COVID-19 group. Multivariate analysis identified BMI, sex, diabetes, severe COVID-19 history, PCT, D-D, and IL-17 as independent risk factors for poor outcomes. Sepsis patients with a history of severe COVID-19 exhibit more severe disease, immune dysregulation, coagulation abnormalities, and increased mortality, indicating long-term detrimental effects of prior infection on sepsis prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.